Skip to main content
S 516 116th Congress Senate Health Criminal justice information and records Drug trafficking and controlled substances Health information and medical records Health personnel Intergovernmental relations Licensing and registrations Medical ethics Prescription drugs State and local government operations

Prescription Drug Monitoring Act of 2019

Introduced: February 14, 2019 Introduced by: Klobuchar, Amy Democratic · Minnesota See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 14, 2019
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Feb 14, 2019
Introduced in Senate
 Plain-English summary Congressional Research Service

Prescription Drug Monitoring Act of 2019

This bill expands the notification and reporting requirements with respect to potentially addictive prescription drugs for states receiving funds for a Prescription Drug Monitoring Program (PDMP). Dispensers of these drugs, which includes substances listed in schedule II, III, or IV of the Controlled Substances Act, must consult with the PDMP before starting treatment involving such drugs and report each prescription of such drugs to the PDMP within 24 hours.

The state agency administering a PDMP must analyze reported data for patterns of controlled substance misuse or abuse and provide certain information to law enforcement, the public, and other states.

What's happening now February 14, 2019

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Committees of jurisdiction 1
 Cosponsors 1
All 1 Independent 1